Full Press Release Details
KalVista Pharmaceuticals Reports Fiscal First Quarter Results
Portfolio of Oral Plasma Kallikrein Inhibitors for Treatment of Hereditary Angioedema Continues to Advance
Intravitreal Diabetic Macular Edema Candidate KVD001 Remains on Track for Phase 2 in 2017
Cambridge, MA, USA and Porton Down, UK., September 14, 2017 KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal first quarter ended July 31, 2017.
We continue to make progress with our portfolio of oral plasma kallikrein inhibitors in pursuit of our goal of a best-in-class oral therapy for hereditary angioedema, said Andrew Crockett, Chief Executive Officer of KalVista. We are completing the first-in-human trial of KVD818 and plan to evaluate final data and determine future development plans as we continue to advance our additional molecules. KVD900 remains on track to be our next candidate to
enter clinical testing, with a regulatory filing before the end of 2017, and there will be at least one additional candidate entering the clinic in 2018. We also continue preparations for the Phase 2 clinical trial for our diabetic macular edema
program candidate KVD001, which will initiate this year.
First Quarter and Recent Business Highlights:
Fiscal First Quarter Financial Results:
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors
for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company has created a structurally diverse
portfolio of oral plasma kallikrein inhibitors from which it plans to select multiple drug candidates to advance into clinical trials for HAE. The first candidate of this planned portfolio of programs, KVD818, is currently in a first-in-human study and additional program candidates are in preclinical development. KalVista s most advanced program, an intravitreally administered plasma kallikrein
inhibitor known as KVD001, has successfully completed its first-in-human study in patients with DME and is being prepared for Phase 2 studies in 2017.
For more information, please visit www.kalvista.com.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: anticipate,
intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may,
should, will and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking
statements include, among others, available funding and future clinical trial timing and results. Further information on potential risk factors that could affect our business and its financial results are detailed in the annual report on Form 10-K filed on July 27, 2017, our most recent Quarterly Report on Form 10-Q, and other reports as filed from time to time with the Securities and Exchange Commission.
We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
KalVista Pharmaceuticals, Inc.
Leah Monteiro, Corporate Communications & Investor Relations